



Company Profile

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases.

The Actinogen Medical management team and clinical and scientific advisory boards include world-renowned Alzheimer's disease and dementia researchers, and industry specialists in drug development and clinical trial management.

Actinogen Medical's lead drug candidate Xanamem™ has been specifically designed to reduce production of excess cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer's disease.

Actinogen Medical is currently conducting a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of 10mg once daily of Xanamem™ in subjects with mild dementia due to Alzheimer's disease.

The trial, named XanADu, will enrol 174 patients at 25 research sites across Australia, the UK and the USA. Recruitment and treatment of patients began in 2017 and is expected to complete in Q4 CY18, with results expected in Q2 2019.

For more information visit www.actinogen.com.au

For more information on the XanADu trial visit www.clinicaltrials.gov with identifier: NCT02727699

Board/Key Personnel

Dr Geoffrey Brooke
Non-Executive Chairman

Dr Bill Ketelbey
*Chief Executive Officer
and Managing Director*

Dr Jason Loveridge
Non-Executive Director

Dr George Morstyn
Non-Executive Director

Speaker Profile



Dr Bill Ketelbey CEO & Managing Director

Dr. Bill Ketelbey is a highly experienced and successful healthcare, biotech and pharmaceutical industry professional, with more than 30 years' experience in the sector.

He is the CEO and Managing Director of ASX-listed biotech, Actinogen Medical, developing a novel therapy for the treatment of Alzheimer's disease and cognitive impairment associated with other neurodegenerative and metabolic diseases. Prior to joining Actinogen Medical, Dr. Ketelbey was Regional Vice President of Medical Affairs at Pfizer covering Japan, Canada, Korea, Australia and New Zealand and Country Medical Director for Pfizer Australia and New Zealand.

Dr. Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of

numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer's disease. At Pfizer, Dr. Ketelbey led the Australian/New Zealand clinical development and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer's disease therapy locally and globally.

Dr. Ketelbey has a Medical Degree from the University of the Witwatersrand, South Africa, is a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom, has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.

Dr. Ketelbey is also a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and Chair of the WIMR IP & Commercialisation Committee.